Elevated Serum or Plasma Sodium
Excessive parenteral sodium administration in an unconscious patient whose thirst mechanism is absent.
Excessive use of diuretics or other drugs leading to water loss in the patient who cannot compensate by intake of water.
Diabetes insipidus may be central (neurogenic), acquired nephrogenic, or congenital nephrogenic.
Mineralocorticoid or glucocorticoid excess from primary hyperaldosteronism and Cushing syndrome with or without ectopic adrenocorticotropic hormone (ACTH) production.
Insensible water loss through the skin in the patient unable to obtain water or swallow.
Clinical findings progress from somnolence to confusion, coma, and respiratory paralysis as the hypernatremia worsens.
Commonly Encountered Situations
Hypernatremia most frequently occurs in an ICU when excess intravenous (IV) sodium is given to an unconscious patient.
Suggested Additional Lab Testing
Urinary electrolytes to assess for diabetes insipidus.
Serum aldosterone to identify primary hyperaldosteronism 24-hour urine free cortisol to identify Cushing syndrome, with or without ectopic ACTH production.
Copyright © 2017, 2013 Decision Support in Medicine, LLC. All rights reserved.
No sponsor or advertiser has participated in, approved or paid for the content provided by Decision Support in Medicine LLC. The Licensed Content is the property of and copyrighted by DSM.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Patient-Reported Outcomes in Oncology Expected to Make Regulatory Waves
- Metastatic Prostate Cancer Responds to Novel Radiation Therapy
- FDA Provides Update on Breast Implant-Associated Anaplastic Large Cell Lymphoma
- Q&A With Mark B. Gerstein, PhD, on Diagnostic Genomic vs Exomic Sequencing
- Investigational Antiandrogen Drug Delays Metastasis in CRPC
- Tivozanib Offers Superior Outcomes in Refractory Metastatic Renal Cell Carcinoma
- First-Line Pembrolizumab Shows Promise in Non-Clear Cell RCC
- Early Tumor Shrinkage With Cabozantinib Improves Survival in Renal Cell Carcinoma
- Combo Superior to Sunitinib in Advanced Renal Cell Carcinoma
- Nivolumab-Ipilimumab Survival Benefit in Advanced RCC Confirmed